Molecular targeted drugs and immunity

Takashi Morisaki, Hideya Onishi, Hiroyuki Suzuki, Mitsuo Katano

Research output: Contribution to journalReview article

Abstract

Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.

Original languageEnglish
Pages (from-to)291-295
Number of pages5
JournalBiotherapy
Volume24
Issue number4
Publication statusPublished - Jul 2010

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Molecular targeted drugs and immunity'. Together they form a unique fingerprint.

  • Cite this

    Morisaki, T., Onishi, H., Suzuki, H., & Katano, M. (2010). Molecular targeted drugs and immunity. Biotherapy, 24(4), 291-295.